ICVB-1042
AXP000055.1 · Oncolytic virus
- Platform
- adenovirus (Ad5, CD46-binding, E2F-dependent replication)
- Originator
- IconOVir Bio
- Sponsor
- IconOVir Bio
Names
| Name | Type | Source |
|---|---|---|
| ICVB-1042 | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 (ICVB-1042)
- Replication
- conditionally replicating
- Modifications
- E2F-dependent replication; CD46-binding capsid
- Transgenes
- YPet reporter protein
- Route
- intratumoral, intravenous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C200413
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05904236 | Safety and Tolerability of Intravenous Administration of ICVB-1042 | Terminated | Phase 1 | 2023-06-01 | 2024-12-11 | 17 | Patients With Advanced Solid Tumors |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39271928 | Nonclinical characterization of ICVB-1042 as a selective oncolytic adenovirus for solid tumor treatment. | Communications biology | 2024 | cited by trial NCT05904236 |
Notes
First patient dosed July 2023 in phase 1 NCT05904236; given intratumorally and intravenously in advanced solid tumours. Carries a YPet reporter per NCIt.
How to cite
ICVB-1042 (AXP000055.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000055.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.